Compare PHAT & PZZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PHAT | PZZA |
|---|---|---|
| Founded | 2018 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2019 | 1995 |
| Metric | PHAT | PZZA |
|---|---|---|
| Price | $11.56 | $32.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $19.50 | ★ $45.00 |
| AVG Volume (30 Days) | 898.5K | ★ 1.3M |
| Earning Date | 05-28-2026 | 05-25-2026 |
| Dividend Yield | N/A | ★ 5.87% |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ 0.90 |
| Revenue | $175,110,000.00 | ★ $2,068,421,000.00 |
| Revenue This Year | $83.18 | $1.13 |
| Revenue Next Year | $61.43 | $0.96 |
| P/E Ratio | ★ N/A | $34.62 |
| Revenue Growth | ★ 216.93 | 14.07 |
| 52 Week Low | $2.21 | $30.16 |
| 52 Week High | $18.31 | $55.74 |
| Indicator | PHAT | PZZA |
|---|---|---|
| Relative Strength Index (RSI) | 39.53 | 41.61 |
| Support Level | $10.65 | $30.18 |
| Resistance Level | $12.77 | $40.23 |
| Average True Range (ATR) | 0.87 | 1.59 |
| MACD | 0.09 | 0.07 |
| Stochastic Oscillator | 14.01 | 37.75 |
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.